Skip to main content
Premium Trial:

Request an Annual Quote

Spotfire, Applied Biosystems Ink Gene Expression Technology Deal

NEW YORK, June 28 (GenomeWeb News) - Spotfire announced today that it has signed a deal with Applied Biosystems under which the companies will combines certain of their technologies for human gene expression research.

 

Under the deal, Applied Biosystems will build analysis capabilities on top of Spotfire's DecisionSite platform, and offer with its newly released Expression Array system 90-day evaluation licenses of the Spotfire's DecisionSite for Function Genomics software.

 

"We are pleased to be aligned with Applied Biosystems as it expands its footprint in the gene expression analysis market with the introduction of the Expression Array System," Christopher Ahlberg, CEO of Spotfire, said in a statement. "By combining these technologies, researchers engaged in microarray analysis will be able to conduct more comprehensive analysis in less time."

 

 

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.